fbpx

Chandnani A, Coburn W, Fichtner J, Hakimi A, Huang J, Liu IT, Neilson T, Su M, Tran W. Mental health and substance use in Colorado healthcare and graduate students during COVID-19: a mixed methods investigation. Harvard Public Health Review. 2021; 27.

Abstract

 

Background: The COVID-19 pandemic continues to impact mental health by exacerbating anxiety, fear, and substance use worldwide. Several studies have demonstrated increased substance use and declining mental health in students abroad, but no investigation has assessed the COVID-19 pandemic’s effects on mental health and substance use in graduate and healthcare students in the United States.

 

Objective: Researchers sought to quantify and qualify the ongoing COVID-19 pandemic’s impacts on Colorado graduate and healthcare students’ mental health and substance use, hypothesizing that greater COVID-19-related fear would correlate with higher substance use rates across metrics.

 

Methods: Investigators utilized an online, institutionally-distributed, mixed-methods survey to assess quantitative and qualitative changes in various mental health metrics and substance use in Colorado healthcare and graduate students during the COVID-19 pandemic from June 2020 to February 2021. An augmented Fear of COVID-19 Scale (FCV-19S) academic survey served as the primary data collection vessel.

 

Results: Students who reported higher levels of depression, exhaustion, loneliness, nervousness, and anger had significantly higher FCV-19S scores. Higher FCV-S19 scores were also significantly associated with increased levels of alcohol consumption, binge drinking, and cannabis use. Qualitative analysis elucidated recurring themes regarding use frequency, substances used, and the reasons underlying use. Further qualitative analysis revealed three common student concerns: worries regarding the length of the pandemic, its social impact, and educational/financial impact.

 

Conclusions: The COVID-19 pandemic has negatively affected the well-being of Colorado healthcare and graduate students, directly increasing substance use while simultaneously exacerbating feelings of fear, anxiety, and helplessness.

 

Introduction

The COVID-19 pandemic has killed more than 2.5 million people to date and presented serious challenges to the health and well-being of people around the world. 1 Studies from COVID-19 and earlier pandemics demonstrate the negative impacts on mental health caused by increased levels of anxiety and fear, among other mediators.2-6 Negative economic, social, and medical consequences of the pandemic—combined with epidemiologic mitigation strategies such as “stay-at-home” orders—have only worsened COVID-19-related mental health outcomes.7-9

 

Healthcare students are at increased baseline risk for anxiety, depression, substance abuse, and suicidal ideation10-17. Medical students in particular have been identified as an at-risk group for high rates of substance abuse18-20 with one study demonstrating that up to 32% of students meet diagnostic criteria for alcohol dependence19. Further studies have indicated that healthcare students experiment with atypical drugs at higher rates than other populations as a coping mechanism21-23. Although the mental health challenges faced by healthcare students are well documented, little evidence is currently available regarding the COVID-19 pandemic’s impact on emotional well-being and substance abuse.

 

Acute fear can be a valuable adaptive behavioral mechanism. However, chronic fear can hasten development of numerous psychiatric disorders in addition to exacerbating pre-existing ones. In the United States, research has shown that areas reporting the highest numbers of COVID-19 cases also report higher levels of COVID-19 fear. 30

 

One previously validated metric that assesses COVID fear is the Fear of COVID-19 Scale (FCV-19S), a 7-item scale that measures the severity of coronavirus-related fear on a 30-point scale (ranging from 5 to 35). Since its initial development,31 the FCV-19S measurement has been validated in diverse populations worldwide32-34—including in U.S. college-aged adults. 35

 

Past research consistently reports high levels of COVID-19 fear among university students,36 nursing students,37 medical students,38-40 and other allied health professional students.27-29, 41 Significant evidence demonstrates negative mental health impacts of COVID-19 and increased substance use among graduate healthcare students abroad.41-44 However, there is minimal investigation into the effects of COVID-19 on substance use in American healthcare and graduate students.

 

This mixed-methods study investigates the intersection of self-reported mental health and substance use during COVID-19 in graduate-level healthcare and social work students in Colorado via an augmented version of the FCV-19S. Specifically, this study quantifies the relationships between substance use and COVID-19 fear score across different academic programs, genders, and clinical experience treating COVID-19 patients. Researchers also employed qualitative methods to identify potential drivers of these relationships. Researchers hypothesized that healthcare and graduate students with higher FCV-19S scores would correlate with higher substance use rates across all demographics, with minimal differences across study variables (e.g., gender, program of study, clinical experience).

 

Methods

 

Survey

 

This investigation assesses the impact of the COVID-19 pandemic on stress, fear, and substance use in graduate-level healthcare and social work students from June 2020 through February 2021. Researchers surveyed students from the University of Colorado Anschutz Medical Center, including the Schools of Dentistry, Medicine, Nursing, Pharmacy, Physical Therapy, Public Health, and the Physician Assistant and Graduate Program, as well as the University of Denver Graduate School of Social Work. The Colorado Multiple Institutional Review Board (COMIRB #20-1297) approved this study. Designers incorporated informed consent into the instrument and required it from respondents prior to starting the survey.

 

A Qualtrics web-based questionnaire was distributed to students via their school emails. Researchers adapted this survey from the Ben Gurion University RADAR Center’s survey that investigated patterns of substance use during lockdowns, using previously validated metrics and allowing for more accurate comparison against similar studies. The questionnaire incorporated  the Fear of COVID-19 Scale (FCV-19S) compiled by Ahorsu et al., 31 which evaluates seven items on a 5-point Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree) for a total possible score of 35, with higher scores corresponding to greater fear. Researchers selected this already-validated survey and corresponding metrics for prompt distribution to students at the beginning of the pandemic. The survey asked general demographic questions followed by queries on anxiety levels, emotional well-being, and types of substance use pre- and post-COVID-19; other confounding factors were not identified or accounted for in the survey collection. The survey also contained a free-response section for students to discuss contributors to self-reported fear and stress as well as substance use patterns. The complete questionnaire is included in the Appendix.

 

Each academic program disseminated the survey to its students approximately once per month, though the survey was coded such that each student could only respond once. All data was anonymously entered and analyzed. To increase response rates, researchers promoted a chance to win two $25 Amazon gift cards through a post-survey raffle.

 

Quantitative Analysis

 

Researchers conducted descriptive statistics using frequencies and percentages for categorical data. Statisticians summarized continuous data with means and standard deviations and medians with minimum and maximum values (Appendix Table 1). They further analyzed FCV-19S summary statistics for skewness and kurtosis to ensure statistical reliability.  Independent t-tests assessed for differences in FCV-19S scores based on paired categorical variables (e.g., answering “yes” or “no” for increased depression). The O’Brien, Brown-Forsythe, Levene, and Bartlett tests assessed the equal variance assumption and Welch’s t-test assessed unequal variances. Analysis of variance (ANOVA) tests analyzed differences in FCV-19S scores based on multi-category variables (e.g., Academic Program). Pearson’s chi-square tests assessed for differences in categorical response rates (e.g., answering “yes” or “no” for increased alcohol intake). Quantitative analysis used JMP Pro 14 at α=0.05 significance level. Of note, the study instrument failed to account for confounding factors, such as socioeconomic status, prior mental health diagnoses, or other potentially confounding variables. As such, researchers were unable to statistically modify results to account for such factors.

 

Qualitative Analysis

 

Researchers utilized grounded-theory methodology to review the free response questions and developed individual code books through ATLAS.ti. After individual review, the researchers discussed and recorded common themes from students’ free responses.

 

Survey respondents had the opportunity to provide short written responses to two main topics: “If you feel excess stress or anxiety from the COVID-19 pandemic, please tell us about your condition,” and “If you have used alcohol and/or other substances to reduce COVID-19 stress or anxiety, please tell us about your pattern of use.” Researchers extracted two primary themes and three respective sub themes from the free-response data. These were coded as follows for the qualitative analysis: (1) concerns surrounding COVID-19 and (2) patterns of substance use. Subcodes were identified based on frequency of common themes.

 

Results

 

Quantitative Results

 

Investigators enrolled 918 students from nine academic programs at the University of Colorado Anschutz Medical Campus and University of Denver Graduate School of Social Work. Seven respondents indicated that they were not enrolled in Spring 2020 graduate-level courses, and their responses were excluded from the final analysis.

 

The survey sample consisted of professional healthcare students with an average age of 27.73 years and standard deviation of 5.27 years (Table 1). Roughly three-quarters (74.67%) of respondents identified as female, 24.22% as male, and 1.10% as sexual minorities (non-binary or transgender). More than 70% (70.56%) of survey respondents self-identified as White, 17.86% as Asian, 7.61% as Hispanic or Latino, and 2.54% as Black or African American. Over half of respondents (51.59%) identified as “not religious,” 30.63% as “somewhat religious,” and 17.78% as “religious or very religious.” Notably, only 11.64% of respondents reported clinical experience treating COVID-19 patients. More than 74% (74.09%) of 911 included surveys were fully completed—and of the 25.91% of incomplete surveys the median completion percentage was 94%. Average response rates were 26.31% (ranging from 9.24% for public health to 50.00% for nursing) based on Fall 2018 enrollment data (n=5202), adjusted to remove one cohort from each program (adjusted to n=3462) as the graduating students from each cohort did not get an opportunity to fill out the survey.

Table 1. Respondent Demographic Characteristics

                                                                                               n = 911

Variable n (%)
Age
            Mean ± SD 27.73 ± 5.27
            Median, Range 26, 20­­-56
Gender
            Female 678 (74.67)
            Male 220 (24.22)
            Non-binary or transgender 10 (1.09)
Ethnicity
            White 640 (70.56)
            Asian 162 (17.86)
            Hispanic or Latino 69 (7.61)
            Black or African American 23 (2.54)
            American Indian or Alaska Native 8 (0.88)
            Native Hawaiian or other Pacific Islander 5 (0.55)
Strength of religious identification
            Not religious 470 (51.59)
            Somewhat religious 279 (30.63)
            Religious/very religious 162 (17.78)
Academic Program
            Medicine 205 (22.50)
            Dentistry 161 (17.67)
            Graduate School 132 (14.49)
            Nursing 125 (13.72)
            Social Work 119 (13.06)
            Pharmacy 87 (9.55)
            Physician Assistant 31 (3.40)
            Physical Therapy 28 (3.07)
            Public Health 23 (2.53)
Clinical experience treating COVID-19 patients
            No 805 (88.36)
            Yes 106 (11.64)
Fully completed survey
            Yes 675 (74.10)
            No 236 (25.91)
Percent progress of uncompleted surveys
            Mean ± SD 81.64 ± 1.38
            Median, Range 94, 0-95

 

Nearly six in ten (58.66%) students reported feeling more depressed, 67.55% more exhausted, 66.74% more lonely, 65.47% more nervous, and 50.23% more angry due to COVID-19 (Table 2). Those who reported feeling more depressed, exhausted, lonely, nervous, or angry all reported higher mean FCV-19S scores that reached statistical significance relative to those who denied such feelings (p<0.0001).

 

Table 2. Mean FCV-19S Score by Response to Change in Feelings

“During the last 3 months or so, because of COVID-19, have you felt more…?”                COVID-19 Fear Value,

Mean ± SD

dF t n (%)
Depressed*** 829.63 11.60
            Yes 18.24 ± 5.16 508 (58.66)
            No 14.44 ± 4.45 358 (41.34)
Exhausted*** 686.54 11.64
            Yes 17.92 ± 5.25 585 (67.55)
            No 14.10 ± 4.12 281 (32.45)
Lonely*** 864 8.01
            Yes 17.65 ± 5.16 578 (66.74)
            No 14.73 ± 4.82 288 (33.26)
Nervous*** 678.84 16.32
            Yes 18.48 ± 4.81 567 (65.47)
            No 13.31 ± 4.22 299 (34.53)
Angry*** 842.01 8.28
            Yes 18.48 ± 4.81 435 (50.23)
            No 13.31 ± 4.22 431 (49.77)

*** Indicates intragroup difference with p < 0.0001.

 

Nearly 40% (39.72%) of respondents reported increased alcohol intake, 17.72% reported consuming at least five alcoholic drinks on one occasion, and 14.44% reported increased cannabis use due to COVID-19 (Figure 1; Appendix Table 2). Moreover, these activities were associated with statistically significantly higher FCV-19S scores of p<0.0001, p<0.0001, and p=0.0003, respectively (Figure 2). Of the population that reported using alcohol less than once per month prior to COVID-19, 10.00% reported using more alcohol because of COVID-19 (Appendix Table 3). Similarly, 4.22% of respondents who reported using cannabis less than once per month prior to COVID-19 reported using more cannabis because of COVID-19.

Figure 1. Change in Substance Use by Response to the Question: “Because of COVID-19, During the Last Three Months, Have You Used Any of the Following Substances More Than Usual?”

Figure 2. Mean FCV-19S Score by Response to the Question: “Because of COVID-19, During the Last Three Months, Have You Used Any of the Following Substances More Than Usual?

* Error bars represent 95% confidence interval

** Indicates p < 0.01

*** Indicates p < 0.0001

 

Figure 3 displays the mean FCV-19S score by gender, school program, and clinical experience in treating COVID-19. Gender correlated with a significant difference in mean FCV-19S scores; women demonstrated mean scores of 16.83 ± 5.80 and men reported mean scores of 13.82 ± 5.66. Of note, students identifying as transgender/nonbinary did not provide adequate response rates for FCV-19S/substance use analysis.

 

Dental, medical, and pharmacy students scored the lowest on the FCV-19S, with mean scores and standard deviations of 14.82 ± 5.46, 15.04 ± 6.19, and 15.17 ± 6.26, respectively. Social work and public health students scored the highest on the FCV-19S, with mean scores of 18.11 ± 6.05 and 18.04 ± 5.10, respectively. Interestingly, clinical experience with treating COVID-19 patients correlated with significantly lower mean FCV-19S scores (14.70 ± 5.26) relative to those without clinical experience (16.31 ± 6.02; p<0.0001). Finally, students who reported increased alcohol use, cannabis use, and binge drinking all reported higher mean FCV-19S scores in a statistically significant fashion compared to respondents who denied such increased use.

 

Figure 3. Mean FCV-19S Score by Gender, Academic Program, and Clinical Experience Treating COVID-19 Patients

* Error bars represent 95% confidence interval** Indicates p < 0.01

*** Indicates p < 0.0001

 

Qualitative Results

 

Students expressed three main qualitative themes regarding COVID-19 concerns: the duration of the pandemic, its impact on education/finances, and its social impact. Deductive coding elucidated three additional themes in response to the substance use question: frequency of use, substances used, and reasons for change. Table 3 presents a full list of codes and subcodes with direct quotes from students.

 

Concerns Surrounding COVID-19

 

Common student concerns included the uncertainty surrounding the pandemic’s duration, family health issues, asymptomatic spread, and media and government responses. Along with fears of family members contracting the virus, many participants indicated frustration with the lack of urgency shown by the general community, citing lack of social distancing/mask wearing and nonchalant attitudes towards the pandemic as issues of key concern. Many also expressed unease regarding perceived delayed responses by the governmental officials who handled the pandemic in its early phases. Respondents specifically felt that misinformation became pervasive during COVID-19 and that an overall “politicization” of the pandemic occurred.

 

Student responses highlighted a second common theme––concerns regarding the pandemic’s impact on their educational training, current finances, and future job prospects. Some noted a decrease in motivation and perceived a decline in lecture quality regarding online coursework. Due to decreased in-person clinical experiences, many worried that they would lack the appropriate training upon graduation. Job loss and diminished career prospects also produced significant financial concern in participants. Some questioned the value of continuing their academic training as they balanced current financial burdens with a decline in future job prospects.

 

Finally, many respondents reported adverse impacts on their social relationships and well-being. Students acknowledged the importance of maintaining social distancing protocols but struggled to reconcile this against needs for social interaction. Students cited this dilemma as the cause of increasing depression and anxiety.

 

Patterns of Substance Use

 

Students consistently reported increased substance use frequency. A majority of participants designated alcohol as their primary pandemic coping substance, followed closely by cannabis. Nicotine, stimulants, and sedatives were also mentioned, though at a lower rate. Notably, participants reported evolving patterns of substance use; some became first-time users during the pandemic, while others progressed to usage daily or multiple times per day. Several participants with histories of substance abuse shared that they relapsed during the pandemic. Many respondents reportedly utilized substances to cope, de-stress, reduce anxiety, decrease boredom, aid in sleep, and occupy free time. However, it is worth noting that a small number of students reported no change or even decreased their frequency of substance use during the pandemic.

 

Table 3. Qualitative Analysis Codes, Subcodes, and Examples

Code Subcode Participant Examples
Concerns Surrounding COVID-19 Length of the Pandemic:

¨   Health

¨   Asymptomatic Spread

¨   Is there an end?

¨   Long-term Impacts

¨   Poor government response

¨   Misinformation

¨   Lack of Urgency

Impact on Education/Finance:

¨   Rotations/Clinical Training

¨   Decreased Quality

¨   Job Instability

Social Impact:

¨   Loneliness

¨   Inability to travel

¨   Relationships

·     “I worry for my family members (parents, grandparents, aunts/uncles) getting sick because they are all high risk.”

·     “Concerned about asymptomatic spread of COVID-19 and unintentional harm of others.”

·     “I believe my education is sub-par from what it used to be.”

·     “My concerns are mostly about future prospects and careers as a nurse given I have not had the standard level of clinical experiences.”

·     “Job-related financial concerns as I lost my job and isolation impacting mental health and relationships”

·     “It feels like this will never end and I can’t see the light at the end of the tunnel which makes my depression worse.”

·     “[The pandemic] will be prolonged because government officials are not treating it with the highest priority.”

·     “Our society is not taking the pandemic seriously and are selfishly ignoring masks and social distancing.”

·      “Hard to stay in contact with friends or go traveling to see family.”

Patterns of Substance Use Frequency:

¨   Increased

¨   Relapse

Substances:

¨   Alcohol

¨   Cannabis

¨   Nicotine

¨   Sedatives

¨   Stimulants

Reasons for Changes:

¨   Boredom

¨   Destressing

¨   Sleep Aid

 

·     “During quarantine, I found myself drinking far more than usual. As someone who…suffers from depression and anxiety, my symptoms have intensified, and I felt hopeless…”

·     “I have been drinking more frequently to “destress” and even turned to medical cannabis in order to sleep some nights.”

·     “I mainly smoke weed to help me get through the loneliness and to make work more fun. Xanax has also helped me forget about stuff.”

·     “I’m an alcoholic and relapsed a month ago.”

·     “My Adderall use has increased because focusing at home is more difficult than in class.”

 

Discussion

 

Global trends during the COVID-19 pandemic indicate worsening mental health across populations,6, 8, 9, 24, 25, 29, 30, 33, 45-51 and increasing consumption of alcohol, cannabis, and other recreational substances.52 This investigation demonstrates that American healthcare and graduate students are no exception to these patterns, as more than half of study enrollees report worsening feelings of depression, exhaustion, loneliness, nervousness, and anger. This is unsurprising, as students are burdened with academic pressures and career decisions in addition to the struggles faced by the general public. This study elucidates several significant associations in this population: (1) students with higher fear of COVID-19 had significantly increased substance use, (2) students with direct clinical exposure to COVID-19 had significantly lower fear, and (3) women reported significantly higher fear than men.

 

Qualitative data regarding reasons for use parallels current literature investigating substance use as a coping mechanism.53, 54 The results of this study demonstrate significant increases in reported alcohol use and a significant association of alcohol use with higher FCV-19S scores (17.92 compared to 15.88). However, it is unclear from the present study whether fear drives alcohol use or whether alcohol (or other substance) use predisposes students to higher levels of fear.55, 56 Excess consumption of addictive substances can potentially worsen existing mental health problems.57 This is particularly worrisome in students seeking graduate healthcare degrees, as poor mental health portends both declines in academic performance and reduced completion of academic programs.43

 

The impact of COVID-19 on cannabis use remains a topic of debate. Vanderbruggen et al. note no significant changes in cannabis use in Belgium,58 while Imtiaz et al. report increased cannabis usage among prior users.59 The results of this study demonstrate a statistically significant increase in cannabis usage which more closely mimics findings from the latter. Given the legality of recreational cannabis in Colorado, researchers anticipated significantly greater cannabis use––making the relatively greater increase of alcohol (39.72%) use compared to cannabis use (14.44%) notable. Such differences may be explained by several factors, including ease of access, cultural acceptance, user preference, and school-mandated drug tests. Though cannabis use has been reported as a coping mechanism during times of stress, numerous studies cite that variation in motives impact usage rates.60-62 Associations between cannabis use and increased anxiety may also reduce its popularity as a coping substance. However, the cannabis-anxiety relationship remains a topic of debate.63, 64

 

Although only 11.64% of respondents indicated experience treating COVID-19 patients, the average FCV-19S score in this group was lower (14.70 vs. 16.31) in a statistically significant fashion compared to students who reported no experience treating COVID-19 patients (Appendix Table 6).  This outcome aligns with classical findings that suggest that increased exposure to fear stimuli can result in lower levels of overall fear65-69. This study suggests that a critical component of COVID-19 fear centers around fear of the unknown, and that lower FCV-19S scores in healthcare workers may reflect acclimatization of healthcare workers to increased baseline levels of fear in clinical settings. The results indicate that mean FCV-19S scores were lower among medical, dental, nursing and pharmacy students, and higher among physician assistant, physical therapy, public health, and other graduate students. These findings could be due to a variety of differences, including: program-specific structural differences, availability of student support and social resources, and pre-existing demographic differences.

 

Regarding gender, study results show statistically significant higher mean FCV-19S scores among females compared to males, but with no accompanying difference in substance use changes. This suggests that increased drug use could be associated with other factors related to COVID-19 or higher baseline substance use among males.

 

This study has several limitations. The study design was adapted from a previously validated survey first developed in Israel and used around the world. However, it has been utilized less frequently in the United States and was used “as-is” for expediency. The survey’s response rate of 26.31% may impact generalizability. Additionally, because this survey only targeted students on the Anschutz Medical Campus and social work students from the University of Denver, these findings may not be representative of healthcare students at other schools or, indeed, in other countries. Researchers also did not evaluate the socioeconomic status of respondents or include other potentially confounding variables, such as previous mental health diagnoses, that may predispose vulnerable individuals to declines in mental health and increased rates of substance use. Finally, the results of this study could potentially be influenced by recall and volunteer bias in self-reporting; the survey relied on respondents’ recollections of substance use prior to the pandemic. As such, respondents who were more afraid of, or impacted by, COVID-19 may have volunteered at higher rates to complete the survey and expressed greater substance use rates compared to those who did not.

 

The strengths of this study include capturing responses from a variety of healthcare students on a large medical campus––including medical, dental, pharmacy, nursing, physical therapy, public health, and physician assistant students—as well as social work students from the University of Denver. This study is among the first to evaluate U.S. healthcare students’ responses to the COVID-19 pandemic through the lens of substance use and emotional well-being. Nearly two-thirds of healthcare students surveyed report increased rates of negative emotions due to the pandemic, and high FCV-19S scores indicate a high prevalence of fear and anxiety surrounding COVID-19.

 

Future directions for research include expanding its scope to cover healthcare programs at multiple graduate and undergraduate institutions, both in the United States and abroad, to allow for greater generalizability. Further studies should investigate the temporality of COVID-19-associated substance use, the development of substance use disorders in students, and expand to include current/prior mental health diagnoses. Finally, understanding the changes in fear levels pre- and post-clinical exposure to COVID-19 serves an important role in understanding the “fear of the unknown” and may illuminate mechanisms of professional adaptation necessary for healthcare workers in times of increased stress.

 

Acknowledgements

 

The authors would like to thank Dr. Richard Isralowitz, Director and Professor Emeritus at the Ben Gurion University of the Negev – Regional Alcohol and Drug Abuse Research Center, for inspiration and access to the survey instrument.

 

References

  1. Liu YC, Kuo RL, Shih SR. COVID-19: The first documented coronavirus pandemic in history. Biomed J. Aug 2020;43(4):328-333. doi:10.1016/j.bj.2020.04.007

  2. Goulia P, Mantas C, Dimitroula D, Mantis D, Hyphantis T. General hospital staff worries, perceived sufficiency of information and associated psychological distress during the A/H1N1 influenza pandemic. BMC Infect Dis. Nov 9 2010;10:322. doi:10.1186/1471-2334-10-322

  3. Liao Q, Cowling BJ, Lam WW, Ng DM, Fielding R. Anxiety, worry and cognitive risk estimate in relation to protective behaviors during the 2009 influenza A/H1N1 pandemic in Hong Kong: ten cross-sectional surveys. BMC Infect Dis. Mar 27 2014;14:169. doi:10.1186/1471-2334-14-169

  4. Sprang G, Silman M. Posttraumatic stress disorder in parents and youth after health-related disasters. Disaster Med Public Health Prep. Feb 2013;7(1):105-10. doi:10.1017/dmp.2013.22

  5. Taha S, Matheson K, Cronin T, Anisman H. Intolerance of uncertainty, appraisals, coping, and anxiety: the case of the 2009 H1N1 pandemic. Br J Health Psychol. Sep 2014;19(3):592-605. doi:10.1111/bjhp.12058

  6. Xiong J, Lipsitz O, Nasri F, et al. Impact of COVID-19 pandemic on mental health in the general population: A systematic review. J Affect Disord. Dec 1 2020;277:55-64. doi:10.1016/j.jad.2020.08.001

  7. Chevance A, Gourion D, Hoertel N, et al. Ensuring mental health care during the SARS-CoV-2 epidemic in France: A narrative review. Encephale. Jun 2020;46(3):193-201. doi:10.1016/j.encep.2020.04.005

  8. Moser DA, Glaus J, Frangou S, Schechter DS. Years of life lost due to the psychosocial consequences of COVID-19 mitigation strategies based on Swiss data. European psychiatry. 2020;63(1):e58-e58. doi:10.1192/j.eurpsy.2020.56

  9. Weerakoon SM, Jetelina KK, Knell G. Longer time spent at home during COVID-19 pandemic is associated with binge drinking among US adults. The American journal of drug and alcohol abuse. 2020:1-9. doi:10.1080/00952990.2020.1832508

  10. Dyrbye LN, Thomas MR, Shanafelt TD. Systematic review of depression, anxiety, and other indicators of psychological distress among U.S. and Canadian medical students. Acad Med. Apr 2006;81(4):354-73. doi:10.1097/00001888-200604000-00009

  11. Fischbein R, Bonfine N. Pharmacy and Medical Students’ Mental Health Symptoms, Experiences, Attitudes and Help-Seeking Behaviors. Am J Pharm Educ. Dec 2019;83(10):7558. doi:10.5688/ajpe7558

  12. Ludwig AB, Burton W, Weingarten J, Milan F, Myers DC, Kligler B. Depression and stress amongst undergraduate medical students. BMC Med Educ. Aug 27 2015;15:141. doi:10.1186/s12909-015-0425-z

  13. Moutinho IL, Maddalena NC, Roland RK, et al. Depression, stress and anxiety in medical students: A cross-sectional comparison between students from different semesters. Rev Assoc Med Bras (1992). Jan 1 2017;63(1):21-28. doi:10.1590/1806-9282.63.01.21

  14. Puthran R, Zhang MW, Tam WW, Ho RC. Prevalence of depression amongst medical students: a meta-analysis. Med Educ. Apr 2016;50(4):456-68. doi:10.1111/medu.12962

  15. Quek TT, Tam WW, Tran BX, et al. The Global Prevalence of Anxiety Among Medical Students: A Meta-Analysis. Int J Environ Res Public Health. Jul 31 2019;16(15)doi:10.3390/ijerph16152735

  16. Rotenstein LS, Ramos MA, Torre M, et al. Prevalence of Depression, Depressive Symptoms, and Suicidal Ideation Among Medical Students: A Systematic Review and Meta-Analysis. Jama. Dec 6 2016;316(21):2214-2236. doi:10.1001/jama.2016.17324

  17. Strobbe S, Crowley M. Substance Use Among Nurses and Nursing Students: A Joint Position Statement of the Emergency Nurses Association and the International Nurses Society on Addictions. J Addict Nurs. Apr/Jun 2017;28(2):104-106. doi:10.1097/jan.0000000000000150

  18. Ayala EE, Roseman D, Winseman JS, Mason HRC. Prevalence, perceptions, and consequences of substance use in medical students. Med Educ Online. 2017;22(1):1392824. doi:10.1080/10872981.2017.1392824

  19. Jackson ER, Shanafelt TD, Hasan O, Satele DV, Dyrbye LN. Burnout and Alcohol Abuse/Dependence Among U.S. Medical Students. Acad Med. Sep 2016;91(9):1251-6. doi:10.1097/acm.0000000000001138

  20. Schwarzbold ML, Haas GM, Barni RS, et al. At-risk drinking and current cannabis use among medical students: a multivariable analysis of the role of personality traits. Braz J Psychiatry. Apr 2020;42(2):136-144. doi:10.1590/1516-4446-2018-0318

  21. Candido FJ, Souza R, Stumpf MA, et al. The use of drugs and medical students: a literature review. Rev Assoc Med Bras (1992). May 2018;64(5):462-468. doi:10.1590/1806-9282.64.05.462

  22. Castaldelli-Maia JM, Lewis T, Marques Dos Santos N, et al. Stressors, psychological distress, and mental health problems amongst Brazilian medical students. Int Rev Psychiatry. Nov-Dec 2019;31(7-8):603-607. doi:10.1080/09540261.2019.1669335

  23. Papazisis G, Siafis S, Tsakiridis I, Koulas I, Dagklis T, Kouvelas D. Prevalence of Cannabis Use Among Medical Students: A Systematic Review and Meta-analysis. Subst Abuse. 2018;12:1178221818805977. doi:10.1177/1178221818805977

  24. Holingue C, Kalb LG, Riehm KE, et al. Mental Distress in the United States at the Beginning of the COVID-19 Pandemic. American journal of public health (1971). 2020;110(11):1628-e7. doi:10.2105/AJPH.2020.305857

  25. Ornell F, Schuch JB, Sordi AO, Kessler FHP. “Pandemic fear” and COVID-19: mental health burden and strategies. Braz J Psychiatry. 2020;42(3):232-235. doi:10.1590/1516-4446-2020-0008

  26. Shigemura J, Ursano RJ, Morganstein JC, Kurosawa M, Benedek DM. Public responses to the novel 2019 coronavirus (2019-nCoV) in Japan: Mental health consequences and target populations. Psychiatry and clinical neurosciences. 2020;74(4):281-282. doi:10.1111/pcn.12988

  27. Agius AM, Gatt G, Vento Zahra E, et al. Self-reported dental student stressors and experiences during the COVID-19 pandemic. J Dent Educ. Feb 2021;85(2):208-215. doi:10.1002/jdd.12409

  28. Hakami Z, Khanagar SB, Vishwanathaiah S, et al. Psychological impact of the coronavirus disease 2019 (COVID-19) pandemic on dental students: A nationwide study. J Dent Educ. Oct 31 2020;doi:10.1002/jdd.12470

  29. Naser AY, Dahmash EZ, Al‐Rousan R, et al. Mental health status of the general population, healthcare professionals, and university students during 2019 coronavirus disease outbreak in Jordan: A cross‐sectional study. Brain and behavior. 2020;10(8):e01730-n/a. doi:10.1002/brb3.1730

  30. Fitzpatrick KM, Harris C, Drawve G. Fear of COVID-19 and the mental health consequences in America. Psychol Trauma. Aug 2020;12(S1):S17-s21. doi:10.1037/tra0000924

  31. Ahorsu DK, Lin C-Y, Imani V, Saffari M, Griffiths MD, Pakpour AH. The Fear of COVID-19 Scale: Development and Initial Validation. Int J Ment Health Addict. 2020:1-9. doi:10.1007/s11469-020-00270-8

  32. Alyami M, Henning M, Krägeloh CU, Alyami H. Psychometric Evaluation of the Arabic Version of the Fear of COVID-19 Scale. Int J Ment Health Addict. 2020:1-14. doi:10.1007/s11469-020-00316-x

  33. Reznik A, Gritsenko V, Konstantinov V, Khamenka N, Isralowitz R. COVID-19 Fear in Eastern Europe: Validation of the Fear of COVID-19 Scale. Int J Ment Health Addict. May 12 2020:1-6. doi:10.1007/s11469-020-00283-3

  34. Soraci P, Ferrari A, Abbiati FA, et al. Validation and Psychometric Evaluation of the Italian Version of the Fear of COVID-19 Scale. Int J Ment Health Addict. May 4 2020:1-10. doi:10.1007/s11469-020-00277-1

  35. Perz CA, Lang BA, Harrington R. Validation of the Fear of COVID-19 Scale in a US College Sample. Int J Ment Health Addict. Jun 25 2020:1-11. doi:10.1007/s11469-020-00356-3

  36. Gritsenko V, Skugarevsky O, Konstantinov V, et al. COVID 19 Fear, Stress, Anxiety, and Substance Use Among Russian and Belarusian University Students. Int J Ment Health Addict. May 21 2020:1-7. doi:10.1007/s11469-020-00330-z

  37. Savitsky B, Findling Y, Ereli A, Hendel T. Anxiety and coping strategies among nursing students during the covid-19 pandemic. Nurse Educ Pract. Jul 2020;46:102809. doi:10.1016/j.nepr.2020.102809

  38. Choi B, Jegatheeswaran L, Minocha A, Alhilani M, Nakhoul M, Mutengesa E. The impact of the COVID-19 pandemic on final year medical students in the United Kingdom: a national survey. BMC Med Educ. Jun 29 2020;20(1):206. doi:10.1186/s12909-020-02117-1

  39. Nguyen HT, Do BN, Pham KM, et al. Fear of COVID-19 Scale-Associations of Its Scores with Health Literacy and Health-Related Behaviors among Medical Students. Int J Environ Res Public Health. Jun 11 2020;17(11)doi:10.3390/ijerph17114164

  40. Saddik B, Hussein A, Sharif-Askari FS, et al. Increased Levels of Anxiety Among Medical and Non-Medical University Students During the COVID-19 Pandemic in the United Arab Emirates. Risk Manag Healthc Policy. 2020;13:2395-2406. doi:10.2147/rmhp.S273333

  41. Zolotov Y, Reznik A, Bender S, Isralowitz R. COVID-19 Fear, Mental Health, and Substance Use Among Israeli University Students. Int J Ment Health Addict. Jun 15 2020:1-7. doi:10.1007/s11469-020-00351-8

  42. Lasheras I, Gracia-García P, Lipnicki DM, et al. Prevalence of Anxiety in Medical Students during the COVID-19 Pandemic: A Rapid Systematic Review with Meta-Analysis. Int J Environ Res Public Health. Sep 10 2020;17(18)doi:10.3390/ijerph17186603

  43. Reverté-Villarroya S, Ortega L, Lavedán A, et al. The influence of COVID-19 on the mental health of final-year nursing students: comparing the situation before and during the pandemic. International journal of mental health nursing. 2021;doi:10.1111/inm.12827

  44. Yehudai M, Bender S, Gritsenko V, Konstantinov V, Reznik A, Isralowitz R. COVID-19 Fear, Mental Health, and Substance Misuse Conditions Among University Social Work Students in Israel and Russia. Int J Ment Health Addict. 2020:1-8. doi:10.1007/s11469-020-00360-7

  45. Chandu VC, Pachava S, Vadapalli V, Marella Y. Development and Initial Validation of the COVID-19 Anxiety Scale. Indian J Public Health. Jun 2020;64(Supplement):S201-s204. doi:10.4103/ijph.IJPH_492_20

  46. Choi EPH, Hui BPH, Wan EYF. Depression and Anxiety in Hong Kong during COVID-19. Int J Environ Res Public Health. May 25 2020;17(10)doi:10.3390/ijerph17103740

  47. Knell G, Robertson MC, Dooley EE, Burford K, Mendez KS. Health Behavior Changes During COVID-19 Pandemic and Subsequent “Stay-at-Home” Orders. International journal of environmental research and public health. 2020;17(17):6268. doi:10.3390/ijerph17176268

  48. Nicolini H. Depression and anxiety during COVID-19 pandemic. Cir Cir. 2020;88(5):542-547. Depresión y ansiedad en los tiempos de la pandemia de COVID-19. doi:10.24875/ciru.M20000067

  49. Peteet JR. COVID-19 Anxiety. J Relig Health. Oct 2020;59(5):2203-2204. doi:10.1007/s10943-020-01041-4

  50. Sher L. COVID-19, anxiety, sleep disturbances and suicide. Sleep Med. Jun 2020;70:124. doi:10.1016/j.sleep.2020.04.019

  51. Sherman AC, Williams ML, Amick BC, Hudson TJ, Messias EL. Mental health outcomes associated with the COVID-19 pandemic: Prevalence and risk factors in a southern US state. Psychiatry research. 2020;293:113476-113476. doi:10.1016/j.psychres.2020.113476

  52. Taylor S, Paluszek MM, Rachor GS, McKay D, Asmundson GJG. Substance use and abuse, COVID-19-related distress, and disregard for social distancing: A network analysis. Addict Behav. Mar 2021;114:106754. doi:10.1016/j.addbeh.2020.106754

  53. Colder CR, Lee YH, Frndak S, Read JP, Wieczorek WF. Internalizing symptoms and cannabis and alcohol use: Between- and within-person risk pathways with coping motives. J Consult Clin Psychol. Jul 2019;87(7):629-644. doi:10.1037/ccp0000413

  54. Heggeness LF, Lechner WV, Ciesla JA. Coping via substance use, internal attribution bias, and their depressive interplay: Findings from a three-week daily diary study using a clinical sample. Addict Behav. Feb 2019;89:70-77. doi:10.1016/j.addbeh.2018.09.019

  55. Ray MH, Hanlon E, McDannald MA. Lateral orbitofrontal cortex partitions mechanisms for fear regulation and alcohol consumption. PLoS One. 2018;13(6):e0198043. doi:10.1371/journal.pone.0198043

  56. Scarlata MJ, Lee SH, Lee D, et al. Chemogenetic stimulation of the infralimbic cortex reverses alcohol-induced fear memory overgeneralization. Sci Rep. Apr 30 2019;9(1):6730. doi:10.1038/s41598-019-43159-w

  57. Pollard MS, Tucker JS, Green JHD. Changes in Adult Alcohol Use and Consequences During the COVID-19 Pandemic in the US. JAMA network open. 2020;3(9):e2022942-e2022942. doi:10.1001/jamanetworkopen.2020.22942

  58. Vanderbruggen N, Matthys F, Van Laere S, et al. Self-Reported Alcohol, Tobacco, and Cannabis Use during COVID-19 Lockdown Measures: Results from a Web-Based Survey. Eur Addict Res. 2020;26(6):309-315. doi:10.1159/000510822

  59. Imtiaz S, Wells S, Rehm J, et al. Cannabis Use During the COVID-19 Pandemic in Canada: A Repeated Cross-sectional Study. J Addict Med. Dec 14 2020;doi:10.1097/adm.0000000000000798

  60. Bresin K, Mekawi Y. Do marijuana use motives matter? Meta-analytic associations with marijuana use frequency and problems. Addict Behav. Dec 2019;99:106102. doi:10.1016/j.addbeh.2019.106102

  61. Glodosky NC, Cuttler C. Motives Matter: Cannabis use motives moderate the associations between stress and negative affect. Addict Behav. Mar 2020;102:106188. doi:10.1016/j.addbeh.2019.106188

  62. Szaflarski M, Sirven JI. Social factors in marijuana use for medical and recreational purposes. Epilepsy Behav. May 2017;70(Pt B):280-287. doi:10.1016/j.yebeh.2016.11.011

  63. Crippa JA, Zuardi AW, Martín-Santos R, et al. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol. Oct 2009;24(7):515-23. doi:10.1002/hup.1048

  64. Shalit N, Lev-Ran S. Does cannabis use increase anxiety disorders? A literature review. Curr Opin Psychiatry. Jan 2020;33(1):8-13. doi:10.1097/yco.0000000000000560

  65. den Hollander M, de Jong JR, Volders S, Goossens ME, Smeets RJ, Vlaeyen JW. Fear reduction in patients with chronic pain: a learning theory perspective. Expert Rev Neurother. Nov 2010;10(11):1733-45. doi:10.1586/ern.10.115

  66. Kida S. Reconsolidation/destabilization, extinction and forgetting of fear memory as therapeutic targets for PTSD. Psychopharmacology (Berl). Jan 2019;236(1):49-57. doi:10.1007/s00213-018-5086-2

  67. Norberg MM, Newins AR, Jiang Y, et al. The Scarier the Better: Maximizing Exposure Therapy Outcomes for Spider Fear. Behav Cogn Psychother. Nov 2018;46(6):754-760. doi:10.1017/s1352465818000437

  68. Preusser F, Margraf J, Zlomuzica A. Generalization of Extinguished Fear to Untreated Fear Stimuli after Exposure. Neuropsychopharmacology. Dec 2017;42(13):2545-2552. doi:10.1038/npp.2017.119

  69. Singewald N, Schmuckermair C, Whittle N, Holmes A, Ressler KJ. Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. Pharmacol Ther. May 2015;149:150-90. doi:10.1016/j.pharmthera.2014.12.004

 

Appendix A

 

Distributed Survey

Q1 Were you enrolled in classes at CU Anschutz or at the University of Denver Graduate School of Social Work during the Spring 2020 semester?

Yes

No

 

Q2 What academic program are you currently a member of? (select one)

School of Medicine

School of Dentistry

School of Pharmacy

College of Nursing

Physical Therapy

School of Public Health

Graduate School

Physician Assistant Program

School of Social Work

 

Q3 Coronavirus (COVID-19) affects our health and well-being including the possibility that substances are used to cope with present conditions. Your answers to the following questions will provide useful information for planning and promoting healthy behavior during difficult times. Participation in this survey is voluntary. A donation of $1 will be made to a COVID-19 relief fund for each completed survey received.Anonymity is promised. Completion of the following survey confirms your consent for participation. Please answer each question in the best way possible.

 

Q4 What gender do you identify with?

Male

Female

Transgender

If neither of these fit, include one that does________________________________________________

 

Q5 What is your age? (years)

Age (1)

▼ 18 (1) … 70 (53)

 

Q6 Please select your ethnicity

American Indian or Alaska Native

Asian

Black or African American

Hispanic or Latino

Native Hawaiian or Other Pacific Islander

White

 

Q7 Are you? (check one)

not religious

somewhat religious

religious / very religious

 

Q8 Do you have clinical experience with treating COVID-19 patients?

Yes

No

 

Q9 On a scale from 1(strongly disagree) to 5 (strongly agree), please respond to the following statements based on COVID-19 conditions during the LAST 3 MONTHS or so:

Strongly Disagree (1) Disagree (2) Neither agree nor disagree (3) Agree (4) Strongly agree (5)
I am afraid of COVID-19 (1)
It makes me uncomfortable to think about COVID-19 (2)
My hands become clammy when I think about COVID-19 (3)
I am afraid of losing my life because of COVID-19 (4)
When watching news and stories about COVID-19 on social media, I become nervous or anxious (5)
I cannot sleep because I worry about getting COVID-19 (6)
My heart races or palpitates when I think about getting COVID-19 (7)
I fear my university studies will be negatively affected by COVID-19 (8)
I am experiencing excess stress and anxiety due to the impact of COVID-19 on my social and family life (9)

 

Q10  BEFORE COVID-19, did you use any of the following substances at least once a month?

Yes (1) No (2)
Cigarettes (and other tobacco products) (1)
alcohol (e.g. beer, wine, hard liquor) (2)
cannabis (3)
medical cannabis (4)
Ritalin (or similar) (5)
pain relievers (e.g., oxycodone, codeine) (6)
sedatives/tranquilizers (e.g., benzodiazepine) (7)

 

Q11 BECAUSE of COVID-19, during the LAST 3 MONTHS, have you used any of the following substances more than usual?

Yes (1) No (2)
Cigarettes (and other tobacco products) (1)
alcohol (e.g. beer, wine, hard liquor) (2)
cannabis (3)
medical cannabis (4)
Ritalin (or similar) (5)
pain relievers (e.g. oxycodone, codeine) (6)
sedatives/tranquilizers (e.g. benzodiazepine) (7)

 

Q12 During the LAST 3 MONTHS, have you had 5 or more alcoholic drinks during one drinking occasion/event because of COVID-19 related impacts on your life?

Yes

No

 

Q16 During the LAST 3 MONTHS or so, because of COVID-19, have you felt MORE:

Yes (4) No (5)
Depressed (1)
Exhausted (2)
Lonely (3)
Nervous (4)
Angry (5)

 

 

Q13 If you feel excess stress or anxiety due to COVID-19, please tell us about your condition.

________________________________________________________________

 

Q14 If you have used alcohol and/or other substances to reduce COVID-19 stress or anxiety please tell us about your pattern of use (e.g. what substance, how much, and how often).

 

Q15 What other concerns do you have about COVID-19?

 

Thank you for your cooperation and stay well, please.

 

Our study is also hosting several focus groups, discussing COVID-19 coping methods, stress, and anxiety. These focus groups will be a single session, with 1-1.5 hours of discussion. If you are interested in participating, please enter your email below and a member of our team will be in contact with you. Participation is voluntary.

 

Thank you for participating in our study. If you would like to enter a raffle for a $25 Amazon gift card, copy and paste the link below:

 

https://docs.google.com/forms/d/e/1FAIpQLScPG005vxm9Mw6cwVFIv5VfktTTppnQGXzOwMAYPI035BRbVg/viewform

 

Appendix Table 1. Summary Statistics for FCV-19S Scale Items

                                                                      n = 885
“Based on COVID-19 conditions during the last 3 months or so…”   Skewness Kurtosis Minimum value selection,

 n (%)

Maximum value selection,

n (%)

“I am afraid of COVID-19” 3.30 ± 1.08 -0.54 -0.61             58 (6.55) 74 (8.36)
“It makes me uncomfortable to think about COVID-19” 2.73 ± 1.13 0.09 -1.02 130 (14.69) 36 (4.07)
“My hands become clammy when I think about COVID-19” 1.70 ± 0.77 1.06 1.17 124 (14.01) 3 (0.34)
“I am afraid of losing my life because of COVID-19” 2.22 ± 1.09 0.66 -0.44 82 (9.27) 22 (2.49)
“When watching news and stories about COVID-19 on social media, I become nervous or anxious” 3.14 ± 1.20 -0.37 -1.02 65 (7.34) 79 (8.93)
“I cannot sleep because I worry about getting COVID-19” 1.73 ± 0.86 1.24 1.34 118 (13.33) 6 (0.68)
“My heart races or palpitates when I think about getting COVID-19” 1.85 ± 0.97 1.08 0.45 114 (12.88) 8 (0.90)

 

Appendix Table 2. Mean FCV-19S Score by Response to Change in Substance Use

“Because of COVID-19, during the last three months, have you used any of the following substances more than usual?” COVID-19 Fear Value,

Mean ± SD

dF t n (%)
Alcohol*** 864 5.72
   Yes 17.92 ± 5.25 342 (39.49)
            No 15.88 ± 5.06 524 (60.51)
Cannabis** 862 3.45
            Yes 18.18 ± 5.14 124 (14.35)
            No 16.44 ± 5.21 740 (85.64)
“Consumed more than 5 alcoholic drinks in a single sitting”*** 867 5.36
            Yes 18.69 ± 5.09 154 (17.72)
            No 16.25 ± 5.15 715 (82.28)

** Indicates intragroup difference with p < 0.01.

*** Indicates intragroup difference with p < 0.0001.

 

Appendix Table 3. Change in Substance Use Among Those Who Reported Using Less Than Once Per Month Before COVID-19

“Because of COVID-19, during the last 3 months or so, have you…?”                n (%)
“Used cannabis more than usual”
            Yes 29 (4.22)
            No 658 (95.78)
“Used alcohol more than usual”
            Yes 21 (10.00)
            No 180 (90.00)
 

  

Appendix Table 4. Change in Substance Use

“Because of COVID-19, during the last three months, have you used any of the following substances more than usual?” Total

n (%)

Male

n (%)

Female

n (%)

Cannabis
   Yes 124 (14.44) 27 (13.11) 92 (14.35)
            No 735 (85.57) 179 (86.89) 549 (85.65)
Alcohol
            Yes 342 (39.72) 76 (36.89) 263 (40.90)
            No 519 (60.28) 130 (63.11) 380 (59.1)
Tobacco
            Yes 32 (96.27) 10 (4.88) 22 (3.43)
            No 826 (3.73) 195 (95.12) 619 (96.57)
Ritalin (or similar)
            Yes 17 (1.98) 4 (1.95) 12 (1.88)
            No 840 (98.02) 201 (98.05) 628 (98.13)
Pain relievers (e.g., oxycodone, codeine)
            Yes 2 (0.23) 0 (0.00) 2 (0.31)
            No 854 (99.77) 206 (100.00) 636 (99.69)
Tranquilizers (e.g., benzodiazepine)
            Yes 35 (4.08) 7 (3.43) 27 (4.20)
            No 824 (95.92) 197 (96.57) 616 (95.80)

*None of the above substances exhibited statistically significant use patterns between males and females using Pearson’s chi-squared test  

 

Appendix Table 5. Mean FCV-19S by Selected Variables

Variable COVID-19 Fear Value,

Mean ± SD

Gender
            Female 16.83 ± 5.80
            Male 13.82 ± 5.66
            Non-binary or transgender 15.90 ± 8.12
Academic Program
            Medicine 15.04 ± 6.19
            Dentistry 14.82 ± 5.46
            Graduate School 17.77 ± 5.43
            Nursing 15.57 ± 5.83
            Social Work 18.11 ± 6.05
            Pharmacy 15.17 ± 6.26
            Physician Assistant 17.52 ± 5.28
            Physical Therapy 17.57 ± 5.62
            Public Health 18.04 ± 5.10
Clinical experience treating COVID-19 patients
            No 16.31 ± 6.02
            Yes 14.70 ± 5.26
Used alcohol more than usual?
            Yes 17.92 ± 5.25
            No 15.88 ± 5.06
Used cannabis more than usual?
            Yes 18.18 ± 5.14
            No 16.44 ± 5.21
Consumed more than 5 alcoholic drinks in one sitting because of COVID-19 related impacts on your life more than usual?
            Yes 18.69 ± 5.09
            No 16.25 ± 5.15

 

Appendix Table 6. Analysis of Variance Test for Mean FCV-19S Score by Gender, Academic Program, and Clinical Experience Treating COVID-19 Patients

  dF Sum of Squares Mean Squares F
Gender*** 2 1503.04 751.52 22.37
            Error 905 30397.10 33.59
Academic Program** 1 242.78 242.78 6.89
            Error 909 32037.94 35.25
Clinical Experience Treating COVID-19 Patients*** 8 1663.85 207.98 6.13
            Error 902 30616287 33.94

** Indicates p < 0.01.

*** Indicates p < 0.0001.